Executive Director, AI for Clinical Intelligence and Evidence

We're building a connected, end-to-end Enterprise AI engine - uniting data foundations, AI technology, process reinvention, and business-facing AI to accelerate results across the whole value chain. Success depends on being exceptional connectors: you'll actively leverage existing capabilities, celebrate and promote reuse, export breakthrough ideas across geographies and functions, and obsess over scaling impact rather than building in isolation. If you thrive in high-collaboration environments where your role is to turn complex, cross-functional problems into reusable, enterprise-wide capabilities - and where the measure of success is adoption and scale, not just innovation - you'll have the platform (and sponsorship) to make it real.

The Executive Director, AI for Clinical Intelligence and Evidence is a senior enterprise leader responsible for defining how AstraZeneca designs, validates, scales, and externalizes AI-driven evidence capabilities across the full lifecycle of its medicines. This role establishes and leads a critical capability within the AI to Transform Care (AITC) organization, integrating clinical trial data, real-world data, multimodal biomarker inputs, and advanced analytics into continuously learning evidence ecosystems. Beyond traditional evidence generation, this function is accountable for:

Designing and governing disease-specific and multimodal foundation models that integrate clinical, molecular, imaging, and real-world data to support continuously learning evidence ecosystems.

Defining how these foundation models are validated, regulated, and made HTA- and payer-acceptable.

Translating insights into decision-grade evidence that directly informs development strategy, regulatory interactions, medical planning, access positioning, and lifecycle management.

Orchestrating AI-driven analytical and agentic workflows that transform integrated data into continuously generated, decision-ready evidence embedded within development, regulatory, and commercial processes.

Driving scalable deployment of AI-enabled evidence capabilities across health systems through strategic partnerships (e.g., EMR-embedded solutions, real-world care networks, and federated data ecosystems).

Establishing closed-loop, continuously learning evidence systems that feed real-world outcomes back into development, regulatory, medical, and commercial decision-making.

Defining commercialization pathways for AI-enabled evidence assets, including external value creation models aligned with population health and value-based care frameworks.

The objective is to transition AstraZeneca from episodic evidence generation to continuously learning, AI-enabled evidence infrastructures that support precision medicine, real-time value demonstration, and sustainable market access.

Support all Tier 1 Ph3 and Tier 1 COMMID's with RWE and AI packages for development providing +5pp PTS for clinical relevance and +2 months commercial optimization for launches by 2030

Support Key Disease Area Strategies with AI-enabled RWE packages (e.g., RWE analysis to predict risk of disease progression based on multimodal features)

Influence semantic layers to reflect strategic vision of AISI & AITC

Pioneer AITC, AISI, EDE, Clinical Intelligence and Evidence operating model

Overall, this function positions AI-generated evidence and foundation models not as analytical tools, but as strategic enterprise assets, driving differentiation in development, accelerating access, strengthening payer confidence, and enabling scalable transformation of care.

Typical Accountabilities

1. Strategy, Portfolio & Foundation Model Ownership

As the enterprise lead for AI-enabled evidence across priority therapeutic areas, you will define and execute a multi-year strategy for how AstraZeneca designs, validates, industrializes, and externalizes AI-driven evidence capabilities across the full product lifecycle. You will establish the roadmap for:

How AI capabilities transition from isolated analyses to repeatable, portfolio-wide evidence engines

How AI integrates clinical trial data, real-world data, biomarker information, and multimodal inputs into continuously learning evidence frameworks

How disease-specific and multimodal foundation models are developed, validated, governed, and scaled across the portfolio

How AI-generated evidence assets can be externalized and positioned within health system ecosystems, aligned with population health and value-based care models

For multimodal outcome prediction and disease modeling, you will work in close partnership with the AI Precision for Health team, providing scientific validation leadership, methodological oversight, and evidence translation strategy while ensuring models meet regulatory, medical, and payer standards.

You will align investments toward high-impact assets where AI-generated evidence and foundation models can materially strengthen regulatory positioning, competitive differentiation, and long-term asset value.

2. Integration of Clinical, Real-World & Multimodal Evidence

Establish enterprise standards and scalable operating models to transform multimodal clinical and real-world data into decision-grade evidence. Define and industrialize AI-enabled methodologies to:

Identify responder subgroups and treatment heterogeneity in clinical trials

Model disease progression and predict treatment response using multimodal datasets

Generate synthetic or external control arms when appropriate

Continuously validate trial findings through real-world monitoring

Enable real-time outcome tracking aligned with value demonstration

Ensure all AI-generated evidence is transparent, explainable, reproducible, and methodologically robust.

Critically, define validation frameworks that make AI-enabled evidence and foundation models acceptable to regulators, HTA bodies, and payers, including standards for explainability, performance benchmarking, bias monitoring, and ongoing model recalibration.

3. Governance, Scientific Rigor & Decision Integration

Embed AI-enabled evidence outputs into formal governance forums across development, medical planning, access strategy, and lifecycle management. Define how AI-generated insights are:

Scientifically validated

Explainable and interpreted in context

Translated into development and commercial decisions

Establish enterprise standards for responsible AI use in evidence generation, including model validation, monitoring, transparency, auditability, and human accountability.

Serve as the recognized enterprise authority on AI-driven evidence methodology and its appropriate application.

4. Regulatory, HTA & External Leadership

Position AstraZeneca as a global leader in the responsible use of AI-enabled and real-world evidence.

Engage with regulators and scientific bodies to advance credible and transparent application of AI-driven methodologies across the product lifecycle, including post-approval validation and continuous evidence monitoring.

In close collaboration with the AI for Precision Health team within AI to Transform Care (AITC), support the development of validation frameworks that enable AI-generated evidence and multimodal foundation models to be acceptable to HTA agencies and payer stakeholders. This includes:

Defining methodological standards for robustness, reproducibility, and explainability

Supporting performance benchmarking and bias monitoring frameworks

Ensuring appropriate governance and model recalibration standards

Translating AI-generated outputs into formats aligned with value demonstration and access discussions

Contribute to shaping industry standards for the validation, governance, and responsible deployment of AI-driven evidence approaches, while ensuring alignment with enterprise access and precision healthcare strategies.

5. AI-Enabled Data, Ecosystem & Commercialization Strategy

Define strategic priorities for AI-ready data partnerships aligned to therapeutic and asset-level evidence needs. Establish clear plans for:

Securing harmonized, high-quality multimodal datasets

Integrating clinical, claims, imaging, genomic, and biomarker data into scalable evidence infrastructures

Governing data use under strong compliance and privacy frameworks

Enabling external deployment of AI-enabled evidence solutions within health system platforms where appropriate

Define how AI-generated evidence capabilities and foundation models may create external value - whether through partnerships, ecosystem embedding, or scalable evidence services aligned with health system and payer priorities.

6. Organizational Leadership

Build and lead a multidisciplinary team combining expertise in clinical development, epidemiology, real-world evidence, data science, and advanced analytics. Develop enterprise capability at the intersection of clinical science, AI transformation, and product lifecycle strategy. Foster a culture of scientific rigor, responsible AI use, cross-functional collaboration, and measurable impact. Promote continuous capability development to ensure AstraZeneca remains at the forefront of AI-driven evidence generation.

Education, Qualifications, Skills and Experience

Essential

Advanced degree (PhD, MD, or MSc) in Statistics, Epidemiology, Data Science, Mathematics, or related field.

15+ years of experience in biopharma with deep expertise in clinical development and evidence strategy across the product lifecycle.

Demonstrated leadership of global, matrixed teams with enterprise-level influence.

Proven experience applying AI and advanced analytics to clinical and real-world datasets.

Experience influencing evidence planning, and portfolio-level strategy.

Strong understanding of clinical trial design, progression modelling, and RWE applications.

Demonstrated ability to translate complex outputs into clear, decision-ready insights.

Strong knowledge of regulatory and payer expectations for real-world validation, evidence generation, and value demonstration.

Excellent communication, executive presence, and cross-functional alignment capabilities.

Desirable

Experience in oncology, precision medicine, or other biomarker-driven therapeutic areas.

Experience deploying AI-driven evidence capabilities across multiple assets or portfolios.

Experience with synthetic control arm methodologies and comparative modelling.

Experience engaging directly with regulators and HTA bodies on advanced evidence methodologies.

Experience overseeing AI/ML model lifecycle governance, validation, and monitoring in production environments.

Experience building and scaling multidisciplinary teams combining clinical and AI expertise.

Exposure to enterprise data platforms and large-scale multimodal data integration initiatives.

Key Relationships to reach solutions

Internal (to AZ or team)

R&D (Early and Late)

Global Medical Affairs

Commercial and Access

Enterprise AI and Data Enablement teams

Regulatory, Legal, Compliance, PV

External (to AZ)

Regulators and HTA bodies

Strategic data partners (registries, claims, multimodal datasets)

AI and technology collaborators

Academic institutions and consortia

Cross-industry RWE working groups

Office Working Requirements:  When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life-changing medicines. In-person working gives us the platform we need to connect, work at pace and challenge perceptions. That's why we work, on average, a minimum of three days per week from the office. But that doesn't mean we're not flexible. We balance the expectation of being in the office while respecting individual flexibility. Join us in our unique and ambitious world.

The annual base pay for this position ranges from $ 258.157,60 - 387.236,40   Annual USD. Base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience. In addition, our positions offer a short-term incentive bonus opportunity; eligibility to participate in our equity-based long-term incentive program. Benefits offered include a qualified retirement program [401(k) plan]; paid vacation and holidays; paid leaves; and, health benefits including medical, prescription drug, dental, and vision coverage in accordance with the terms and conditions of the applicable plans.

#EAI

Date Posted

10-nov-2026

Closing Date

26-nov-2026 Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.